About
Innervate Radiopharmaceuticals develops PET imaging and therapeutic radiopharmaceuticals, including 18F-metafluorobenzylguanidine (mFBG), aimed at improving detection and management of neuroblastoma and myocardial sympathetic innervation through ongoing clinical trials.
Explore Innervate Radiopharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.